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Abstract 
About 16% of the population in Croatia is older than 65 years. Croatia has no register of 
persons with dementia (PWD), but based on a calculation that 10% of persons over 65 years 
are affected by dementia, the approximate number of PWD would be 80,000, the majority 
being patients with Alzheimer’s disease (AD). Psychogeriatric departments exist in hospitals, 
but there are almost no nursing homes and an insufficient number of daily care centres for 
PWD. Antidementia drugs registered in Croatia are donepezil, rivastigmine and memantine. 
Clinical studies of new antidementia drugs have been conducted in Croatia since 1989. At 
present, studies of several antidementia drugs are underway at different testing stages. 
 
Key words: Alzheimer’s disease; antidementia drugs; cholinesterase inhibitors; Croatia; 
dementia.
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1. Introduction 
In 2001, Croatia had 4,437,460 inhabitants and 15.7% were older than 65 years [1, 2]. The 
same source of information registered 1,455 persons between 95 and 108 years of age. In the 
database of the Croatian Institute for Health Insurance, 806,070 persons older than 65 years 
were registered in December 2006 [3]. The newest estimate for the Croatian population, from 
July 2009, is 4,489,409 [4]. Life expectancy at birth is estimated to be 79 years for the female 
population and 72 years for the male population [4]. 
 
Demographic trends observed over the past 5-6 decades show depopulation, and the overall 
population getting older [5]. An extrapolation of these data to the year 2050 predicts 26.2% 
of people older than 65 years [6]. The above data place Croatia among the oldest populations 
among European countries [7]. 
 
Croatia has no register of persons with dementia (PWD). If 10% of people above 65 years of 
age are affected by dementia [3], the number of PWD would be about 80,000, the majority 
being patients with Alzheimer’s disease (AD) [8]. It is assessed that up to 15,000 PWD live 
in Zagreb [8], the capital of Croatia. 
 
2. Institutional care for people with dementia 
The first Psychogeriatric Department in Croatia was established within the Psychiatric 
Hospital Vrapče in Zagreb in 1959 [9]. The hospital is the oldest and largest psychiatric 
hospital in Croatia; it has been working continuously for 130 years. There are currently 
several psychiatric hospitals with psychogeriatric departments: another one in Zagreb (Sveti 
Ivan) and one close to Zagreb (Popovača), one on the Adriatic coast (Lopača near Rijeka), 
and there are two on the islands of Rab and Ugljan. Croatia, however, has only a few small 
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private nursing homes and several daily care centres for PWD [10]. 
 
It is not known when the term “Alzheimer’s disease” (AD) was first used for diagnosis in 
Croatia. However, it is known that the diagnosis of AD was not at all or very rarely used until 
1978, and patients with AD were referred to as Pre-senile Dementia [11]. At the end of 1978, 
the International Classification of Diseases (ICD-9) [12] became the official classification in 
Croatia and since then the diagnosis of AD became gradually more often applied. 
 
National associations for Alzheimer’s disease have a very important role in AD management 
of all PWD [13]. The Alzheimer Disease Societies Croatia (ADSC) was founded in Zagreb in 
1999 [14], and is functioning on an exclusively voluntary basis [15]. In 2006, ADSC became 
a member of Alzheimer's Disease International (ADI), and in 2009 of Alzheimer Europe 
[16]. 
 
3. Pharmacological treatment of people with Alzheimer's disease 
Five drugs are currently approved by the United States Food and Drug Administration (FDA) 
for the treatment of PWD. These are tacrine, donepezil, rivastigmine, galantamine and 
memantine. All but one (memantine) are cholinesterase inhibitors [17, 18]. All five drugs are 
recommended for use in Croatia, but only three are registered in Croatia: donepezil (Aricept; 
Aricept Evess; Donepezil Pliva; Yasnal), rivastigmine (Exelon Patch) and memantine (Ebixa; 
Memantin Pliva) [19]. However, none of the three is on the reimbursement list of the 
Croatian Institute for Health Insurance [20]. Due to the high cost of these drugs, the majority 
of PWD cannot afford to buy these drugs and are taking supportive, adjuvant or alternative 
medications instead. These are gingko biloba, nootropics (piracetam), anti-inflammatories, 
statins, oestrogens, omega-3 fatty acids, vitamins E and C, nicotinamide adenine dinucleotide 
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(NADH) and trace elements [10]. 
 
The Croatian algorithm for psychopharmacological treatment of AD was introduced in 2006. 
Donepezil constitutes the first-line pharmacotherapy for mild and moderate cognitive 
deficits. If the response is low, rivastigmine and galantamine are the second-line therapy. If 
the answer is low again, adding memantine is recommended. In cases of severe dementia, the 
recommended first-line is memantine augmented by donepezil. If the effect to the combined 
memantine/donepezil therapy is low, application of rivastigmine or galantamine is 
recommended [21]. 
 
Clinical studies of new antidementia drugs have been conducted in Croatia since 1989, and 
some PWD participating in these studies benefit directly from them. The trials began with 
pentoxifylline [22, 23, 24] and continued with propentofylline, donepezil, phenserine-tartrate 
and EVP-6124. Clinical trials will include some novel potential antidementia agents in the 
near future. Some are based on the cholinergic hypothesis and combine acetylcholinesterase 
and serotonin reuptake inhibition (BGC20-1259) or acetylcholinesterase and monoamine 
oxidase inhibition (ladostigil), others belong to the field of passive immunotherapy 
(bapineuzumab). 
 
4. Conclusions 
The predicted world-wide increase in the incidence of dementia, particularly of Alzheimer’s 
disease, is likely to occur also in Croatia, so a better preparedness for the care of PWD is 
certainly required. 
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